Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Sits On $1.4bn Cash, Seeks External Innovation Away From CF

Executive Summary

Vertex – a company currently leading the lucrative cystic fibrosis market and set to retain command of this arena into the foreseeable future – is preparing to replicate its CF success in another therapy area.

You may also be interested in...



Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition

Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.

Experience Counts For VC Success: HealthCap Hits 25 Year Mark

VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Topics

UsernamePublicRestriction

Register

SC098118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel